Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

NEW YORK , April 7, 2023 /PRNewswire/ -- WHY: New York, N.Y., April 7, 2023.

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMGN

Apple

AbbVie

Accenture Plc

Adobe

Agree Realty

Automatic Data Processing

Amazon

Air Products and Chemicals

Ares Capital

Alexandria Real Estate Equities

ASML Hld

AvalonBay Communities

Broadcom

Booz Allen Hamilton Hld

SPDR Bloomberg 1-3 Month T-Bill ETF

Blackrock Inc

Bristol-Myers

Broadridge Financial

British American Tobacco

Blackstone Group

Carrier Global

Crown Castle International

Comcast

CME Group

I'm reviewing my February and March results in this piece. My passive income stream grew by 22.63% in February and by 46.87% in March.

Nicholas Ward's Dividend Growth Portfolio: Special Fixed Income Edition

LeMaitre Vascular

Amgen and LeMaitre Vascular both possess solid product portfolios and pipelines to drive future earnings growth. Their payouts are well-covered by their earnings.

Income Investors: These 2 Stocks Have Quadrupled Their Dividend Payouts Over the Past 10 Years

American Express

McDonald's

The Dow is short for the Dow Jones Industrial Average, a stock index that tracks the largest highly-traded public companies. It is one of the most watched indicators of overall stock market direction and includes 30 of the largest publicly traded firms.

3 Must-Buy Dow Stocks for Your April Buy List

Cisco Systems

Chevron

Disney

Dow Inc

Goldman Sachs

Honeywell

JPMorgan Chase & Co

Travelers

UnitedHealth Group

Verizon

Walgreens

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.” – Dow Jones & Co. These highest-yielding 10 stocks are April's Dogs of the Dow: CSCO, GS, JPM, AMGN, CVX, IBM, DOW, WBA, MMM, and VZ, averaging a 4.44% annual yield.

April Dogs Of The Dow: 2 Buy, 3 Watch

RADNOR, Pa. , April 3, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN).

AMGN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds AMGN Investors of Upcoming Deadline and Urges Investors with Substantial Losses to Contact the Firm

American Electric Power Company

Bank of America

ConocoPhillips

CVS Health

Medtronic

MetLife

Morgan Stanley

Pfizer

PNC Financial Services

Phillips 66

Sempra Energy

Truist Financial

U.S. Bancorp

Vanguard High Dividend Yield ETF

There are 19 stocks on my high-yield watchlist for April 2023. The majority of the stocks on my watchlist are undervalued based on dividend yield theory.

High Yield Stock Watchlist: April 2023

FedEx

Johnson Controls

Altria

Merck

Constellation Brands

Tapestry

With the second quarter officially underway and the S&P 500 trading right back to the top of a trading range that has been in place since the fall, the question is what investors should do now.

7 of Goldman Sachs' Top New Q2 Ideas Also Pay Big, Dependable Dividends

Johnson & Johnson

Coca-Cola

Johnson & Johnson offers investors a 2.9% yield now and a 2-for-1 deal later this year. Amgen offers a 3.5% yield fueled by high-margin pharmaceutical sales.

3 Dow Stocks With Above-Average Dividends Yields to Buy in April

NEW YORK , March 30, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the "Class Period"), of the important May 12, 2023 . SO WHAT: If you purchased Amgen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMGN

Within the next month, Amgen Inc. AMGN is expected to report quarterly earnings at $4 per share on revenue of $6.26 billion, analysts say.

Amgen Options Traders Betting On Stock Rising This Much By April Expiration - Amgen (NASDAQ:AMGN)

Thanks to rising bond yields, investors have rotated out of many risky stocks this month. Bargain hunters may want to take advantage of this temporary pullback to load up on high-quality stocks.

This Blue Chip Dividend Stock Should Return to Form When the Risk Premium Flips

RADNOR, Pa. , March 25, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN).

AMGN Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. Investors of Securities Fraud Class Action Lawsuit

SAN DIEGO , March 25, 2023 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announced that it has filed a class action lawsuit seeking to represent purchasers or acquirers of Amgen Inc. (NASDAQ: AMGN) common stock between July 29, 2020 and April 27, 2022, inclusive (the "Class Period").  Captioned Roofers Local No.

AMGN NOTICE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Amgen Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

NEW YORK , March 24, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the "Class Period"), of the important May 12, 2023 . SO WHAT: If you purchased Amgen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMGN

Despite lower EPS in 4Q 2022 compared with 4Q 2021, Amgen's full-year 2022 financial results were strong. Amgen increased its free cash flow of $8381 million in 2021 by 4% in 2022 and thus, provided the opportunity for more distributions.

Amgen: Revenue Growth Potentials And Financial Performance

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN) ) common stock between July 29, 2020 and April 27, 2022, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)

Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline.

Here's What is Driving Amgen (AMGN) Stock's Outperformance

Amgen expects to lay off >3% of its entire workforce before 1H 2023 - around 750 staff. Management says it has acted in response to rising interest rates and increasing pressure on drug pricing.

Amgen Announces More Layoffs - Why I'd Buy This Dip

News for Amgen Stock (AMGN)